Actinium Pharmaceuticals
ATNM
47 hedge funds and large institutions have $5.18M invested in Actinium Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 20 reducing their positions, and 12 closing their positions.
0.13% less ownership
Funds ownership: 16.99% → 16.86% (-0.13%)
2% less capital invested
Capital invested by funds: $5.27M → $5.18M (-$89.5K)
13% less funds holding
Funds holding: 54 → 47 (-7)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
70% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFG
SNS Financial Group
Minneapolis,
Minnesota
|
+$49.7K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$45.9K |
| 3 |
BlackRock
New York
|
+$28.5K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$23.1K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$1.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$121K |
| 2 |
Renaissance Technologies
New York
|
-$105K |
| 3 |
Two Sigma Investments
New York
|
-$90.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$77.6K |
| 5 |
Goldman Sachs
New York
|
-$69.9K |
ATNM Hedge Fund Activity: Q2 2026 in Review
47 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2026, worth a combined $5.18M — down 1.7% from $5.27M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATNM and 6 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 6 added.
The largest buyer was SNS Financial Group, opening a new position worth an estimated $49.7K. The largest seller was Acadian Asset Management, cutting an estimated $121K.
- 47 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2026, down from 54 in Q1 2026.
- Funds reported $5.18M of Actinium Pharmaceuticals stock for Q2 2026, down 1.7% quarter-over-quarter.
- 6 funds opened new Actinium Pharmaceuticals positions in Q2 2026 and 12 closed out, a net change of -6 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2026 was SNS Financial Group, an estimated $49.7K added.
- The largest Actinium Pharmaceuticals seller in Q2 2026 was Acadian Asset Management, an estimated $121K sold.
Based on aggregated 13F filings for Q2 2026.